×

Cesca Therapeutics to Announce First Quarter Fiscal 2015 Results on November 13, 2014

RANCHO CORDOVA, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal first quarter ended September 30, 2014, on Thursday, November 13, 2014.

Company's Conference Call and Webcast

Management will host a conference call Thursday, November 13, 2014 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal first quarter financial results.

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "Cesca." Mr. Robin C. Stracey, Interim Chief Executive Officer, Mr. Kenneth Harris, President and Mr. Dan Bessey, Chief Financial Officer will be on the call to discuss the first quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately five minutes before the conference call begins.

To listen to the audio webcast of the call during or after the event, please visit: http://cescatherapeutics.com/investors/webcasts-calls/

Replay

A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About Cesca Therapeutics

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. We are a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

CONTACT: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Kirin Smith, ProActive Capital Group + 1-646-863-6519, or ir@cescatherapeutics.com

Source:Cesca Therapeutics Inc.